As of May 26, 2023, Seelos Therapeutics Inc has received a notice from Nasdaq regarding its non-compliance with Rule 5550(a)(2). The rule requires the company to maintain a minimum bid price of $1 per share for its common stock. Unfortunately, Seelos Therapeutics Inc has failed to meet this requirement, resulting in its non-compliance status.
To regain compliance, the company plans to submit a plan to the Nasdaq Hearings Panel as part of the hearing process. As a listed company on the Nasdaq stock exchange, Seelos Therapeutics Inc is obligated to disclose its financial condition, operating results, management compensation, and other information to the Securities and Exchange Commission (SEC).
Currently, the company’s compliance status is listed as “N/A” on Nasdaq’s website, and it is also included in the non-compliant companies list. For those interested in Seelos Therapeutics Inc’s financial data, it can be found on Nasdaq’s website.
SEEL Stock Opens at $0.91 with Fluctuations Between $0.89 and $0.94: SLDB Shows Positive Performance Despite Loss in Profit and Revenue
On May 26, 2023, SEEL stock opened at $0.91 and fluctuated between a low of $0.89 and a high of $0.94, with a volume of 8,311 shares traded. The market capitalization of SEEL was $126.7 million, and the earnings growth for the previous year was +4.84%. However, there was no earnings growth for the current year, and there was no forecast for earnings growth for the next five years. In comparison, SLDB had a positive performance, with an increase in stock price, but its financials showed a loss in profit and revenue.
Seelos Therapeutics Inc (SEEL) Shows Promising Stock Performance with 328.31% Increase in Target Price: Analysts Consensus to Buy Stock Remains Steady Despite Negative Earnings and Zero Sales
On May 26, 2023, Seelos Therapeutics Inc (SEEL) showed promising stock performance, with a median target price of $4.00 from the three analysts offering 12-month price forecasts. This represents a significant increase of 328.31% from the last price of $0.93. The consensus among four polled investment analysts was to buy stock in Seelos Therapeutics Inc, a rating that has remained steady since March. However, it is important to note that Seelos Therapeutics Inc reported negative earnings per share of -$0.09 and zero sales for the current quarter.
Discussion about this post